Mustang Bio, Inc (MBIO) reports that the U.S. Food and Drug Administration (FDA) has approved the Company’s investigational new dug application (IND) in acute myeloid leukemia (AML) blastic plasmacytoid dendritic cell neoplasm (BPDCN) and high-risk myelodysplastic...
MB-102, a CAR T-cell therapy under development by Mustang Bio, Inc. has received orphan drug designation for Acute Myeloid Leukemia (AML). What is MB-102? CD123 is over expressed in 75-89% of AML patients and over 90% in Blastic plasmacytoid dendritic cell neoplasm...
Scientists at VCU Massey Cancer Center found that a novel combination of drugs is effective against acute myeloid leukemia (AML) in preclinical models. The findings, recently published in the Journal of Cancer Research, could lead to new and improved treatments for...
Iqra Farooq with AML Global Portal writes the prognosis of younger patients with acute myeloid leukemia (AML) has improved with the development of allogeneic hematopoietic stem cell transplantation (allo-HSCT) and advanced supportive care. But, in most elderly...
Iqra Farooq of AML Global reports approximately 25% of patients with acute myeloid leukemia (AML) have internal tandem duplication of FMS-like tyrosine kinase 3 (FLT3-ITD) mutations and survival is often inferior due to high relapse rates and short remission periods....
Uro Today reports well known physician Dr. Joseph G. Jurcic, after reviewing the early treatment of acute myelogenous leukemia (AML) with Bi213-Lintuzumab when contrasted with beta-emitters I132 and Y90, found the alpha therapy was far superior in absorbed dose to the...
